(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.42%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
3.31% INR 359.25
Live Chart Being Loaded With Signals
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables...
Stats | |
---|---|
Tagesvolumen | 13 522.00 |
Durchschnittsvolumen | 11 316.00 |
Marktkapitalisierung | 5.78B |
EPS | INR0 ( 2024-02-08 ) |
Nächstes Ertragsdatum | ( INR0 ) 2024-05-27 |
Last Dividend | INR0.500 ( 2019-09-20 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 38.96 |
ATR14 | INR1.579 (0.44%) |
Volumen Korrelation
Kilitch Drugs (India) Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Kilitch Drugs (India) Korrelation - Währung/Rohstoff
Kilitch Drugs (India) Finanzdaten
Annual | 2022 |
Umsatz: | INR1.40B |
Bruttogewinn: | INR648.40M (46.45 %) |
EPS: | INR6.71 |
FY | 2022 |
Umsatz: | INR1.40B |
Bruttogewinn: | INR648.40M (46.45 %) |
EPS: | INR6.71 |
FY | 2022 |
Umsatz: | INR1.14B |
Bruttogewinn: | INR488.01M (42.72 %) |
EPS: | INR4.73 |
FY | 2021 |
Umsatz: | INR685.23M |
Bruttogewinn: | INR312.16M (45.56 %) |
EPS: | INR2.37 |
Financial Reports:
No articles found.
Kilitch Drugs (India) Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR1.000 | 2010-10-14 |
Last Dividend | INR0.500 | 2019-09-20 |
Next Dividend | INR0 | N/A |
Payout Date | 2019-10-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | INR33.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.62 | -- |
Div. Sustainability Score | 4.64 | |
Div.Growth Potential Score | 4.47 | |
Div. Directional Score | 4.56 | -- |
Year | Amount | Yield |
---|---|---|
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.500 | 0.59% |
2019 | INR0.500 | 0.31% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TITAN.NS | Dividend Junior | 2023-07-13 | Annually | 20 | 0.35% | |
PETRONET.NS | Dividend Knight | 2023-08-18 | Semi-Annually | 18 | 2.36% | |
JASH.NS | Dividend Junior | 2023-09-22 | Annually | 7 | 0.57% | |
DBOL.NS | Dividend Junior | 2023-06-23 | Insufficient data to determine frequency | 2 | 0.56% | |
SILINV.NS | Dividend Junior | 2023-08-18 | Annually | 23 | 0.63% | |
MBAPL.NS | Dividend Junior | 2023-09-18 | Annually | 8 | 0.44% | |
GUJAPOLLO.NS | Ex Dividend Junior | 2023-09-22 | Annually | 18 | 0.48% | |
BAYERCROP.NS | Dividend Junior | 2023-08-03 | Annually | 15 | 1.25% | |
PREMIERPOL.NS | Dividend Junior | 2023-09-11 | Sporadic | 9 | 0.39% | |
KAMDHENU.NS | Dividend Junior | 2023-08-14 | Sporadic | 17 | 0.32% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0940 | 1.500 | 8.12 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.124 | 1.500 | 9.73 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 4.20 | 1.000 | 9.56 | 9.56 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.15 | 2.00 | 8.62 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 4.15 | 2.00 | 7.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.486 | 1.000 | 5.24 | 5.24 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.158 | 1.000 | 8.85 | 8.85 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.64 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 39.65 | 1.000 | 6.10 | 0 | [1 - 100] |
returnOnEquityTTM | 0.124 | 2.50 | 9.83 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 4.15 | 2.00 | 8.62 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.15 | 2.00 | 8.62 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.947 | 1.500 | 7.02 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0430 | 1.000 | -1.424 | 0 | [0.1 - 0.5] |
Total Score | 4.47 |
Kilitch Drugs (India)
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.